S01E05 EGFR-Mutated NSCLC Update — FLAURA2 Overall Survival + Sacituzumab Tirumotecan After TKI Resistance

This week on PRISM Rounds, we break down two NEJM trials that reshape decision-making in EGFR-mutated advanced NSCLC—one testing front-line intensification (osimertinib plus platinum–pemetrexed with final overall survival results) and the other addressing post–EGFR-TKI resistance with the Trop-2 antibody–drug conjugate sacituzumab tirumotecan versus platinum–pemetrexed. We then connect the evidence with Roy Herbst’s NEJM editorial to discuss sequencing, tradeoffs (benefit vs toxicity), and practical “Monday morning” takeaways.ArticlesJänne PA, et al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. DOI: 10.1056/NEJMoa2510308. PMID: 41104938. https://pubmed.ncbi.nlm.nih.gov/41104938/Fang W, et al. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. N Engl J Med. DOI: 10.1056/NEJMoa2512071. PMID: 41124220. https://pubmed.ncbi.nlm.nih.gov/41124220/Herbst RS. Navigating the Evolving Landscape of EGFR-Mutated NSCLC. N Engl J Med (Editorial). DOI: 10.1056/NEJMe2514042. PMID: 41467655. https://pubmed.ncbi.nlm.nih.gov/41467655/PRISM Rounds; Journal Club; NEJM; Oncology; Lung Cancer; NSCLC; EGFR; Osimertinib; FLAURA2; Platinum Pemetrexed; Antibody Drug Conjugate; Trop-2; Sacituzumab Tirumotecan; Targeted Therapy; Resistance; Progression-Free Survival; Overall Survival; Clinical Trials; Evidence-Based Medicine; Hematology Oncology